Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

NCT02414165 is registered in ClinicalTrials.gov with Tocagen Inc. as lead sponsor.

NCT NCT02414165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02414165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Lead sponsor
Tocagen Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
November 30, 2015
Completion date
December 20, 2019
Enrollment
403 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma multiforme